Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Last Updated: March 1, 2016; Last Reviewed: March 1, 2016
|Ritonavir (RTV, Norvir)
For additional information see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
Oral Solution (Contains 43% Alcohol by Volume): 80 mg/mL
Capsules: 100 mg
Tablets: 100 mg
|Dosing Recommendations||Selected Adverse Events|
Ritonavir as a Pharmacokinetic (PK) Enhancera:
Drug Interactions (see also the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and http://iasusa.org/sites/default/files/tam/october_november_2015.pdf#page=10)
- Metabolism: Ritonavir is extensively metabolized by and is one of the most potent inhibitors of hepatic cytochrome P450 3A (CYP3A). There is potential for multiple drug interactions with ritonavir.
- Before ritonavir is administered, a patient’s medication profile should be carefully reviewed for potential interactions with ritonavir and overlapping toxicities with other drugs.
- Ritonavir and cobicistat are not interchangeable and may result in different drug interactions.
- Avoid concomitant use of intranasal or inhaled fluticasone because of reports of adrenal insufficiency.1 Use caution when prescribing ritonavir with other inhaled steroids; limited data suggest that beclomethasone may be a suitable alternative to fluticasone when an inhaled/intranasal corticosteroid is required for a patient who is taking ritonavir.2,3
- More common: Nausea, vomiting, diarrhea, headache, abdominal pain, anorexia, circumoral paresthesia, lipid abnormalities
- Less common (more severe): Exacerbation of chronic liver disease, fat maldistribution
- Rare: New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs, pancreatitis, and hepatitis (life-threatening in rare cases). Allergic reactions, including bronchospasm, urticaria, and angioedema. Toxic epidermal necrolysis and Stevens-Johnson syndrome have occurred.4
Resistance to ritonavir is not clinically relevant when the drug is used as a pharmacokinetic (PK) enhancer of other antiretroviral (ARV) medications.
Ritonavir has been approved by the Food and Drug Administration for use in the pediatric population.
Efficacy: Effectiveness in Practice
Use of ritonavir as the sole protease inhibitor (PI) in antiretroviral therapy in children is not recommended. Although ritonavir has been well studied in children as an ARV agent, it is no longer used as a sole PI for therapy because ritonavir is associated with a higher incidence of gastrointestinal toxicity and has a greater potential for drug-drug interactions than other PIs. In addition, poor palatability of the liquid preparation and large pill burden with the capsules (adult dose is six capsules or tablets twice daily) limit its use as a sole PI. However, in both children and adults, ritonavir is recommended as a PK enhancer for use with other PIs or, in adults, with the integrase inhibitor elvitegravir when used in combination with another PI. Ritonavir is a CYP3A4 inhibitor and functions as a PK enhancer by slowing the metabolism of elvitegravir and of the PIs.
Pediatric dosing regimens including boosted fosamprenavir, tipranavir, darunavir, atazanavir and a PI co-formulation, lopinavir/ritonavir (LPV/r), are available (see individual PIs for more specific information). Dosing of ritonavir when used as a PK enhancer of elvitegravir in a boosted PI regimen is available for adults (see elvitegravir section).
Full-dose ritonavir has been shown to prolong the PR interval in a study of healthy adults who were given ritonavir at 400 mg twice daily.4 Potentially life-threatening arrhythmias in premature newborn infants treated with LPV/r have been reported; thus, LPV/r should not be used in this group of patients.5,6 Co-administration of ritonavir with other drugs that prolong the PR interval (e.g., macrolides, quinolones, methadone) should be undertaken with caution because it is unknown how co-administering any of these drugs with ritonavir will affect the PR interval. In addition, ritonavir should be used with caution in patients who may be at increased risk of developing cardiac conduction abnormalities, such as those with underlying structural heart disease, conduction system abnormalities, ischemic heart disease, or cardiomyopathy.
- Bernecker C, West TB, Mansmann G, Scherbaum WA, Willenberg HS. Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature. Exp Clin Endocrinol Diabetes. 2012;120(3):125-127. Available at http://www.ncbi.nlm.nih.gov/pubmed/22328106.
- Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr. 2013;63(3):355-361. Available at http://www.ncbi.nlm.nih.gov/pubmed/23535292.
- Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013;14(9):519-529. Available at http://www.ncbi.nlm.nih.gov/pubmed/23590676.
- Changes to Norvir labeling. AIDS Patient Care STDS. 2008;22(10):834-835. Available at http://www.ncbi.nlm.nih.gov/pubmed/18924248.
- Lopriore E, Rozendaal L, Gelinck LB, Bokenkamp R, Boelen CC, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS. 2007;21(18):2564-2565. Available at http://www.ncbi.nlm.nih.gov/pubmed/18025905.
- McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, Patel JA. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009;28(12):1127-1129. Available at http://www.ncbi.nlm.nih.gov/pubmed/19820426.